Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
grade A 64.0 5.12% 3.12
BHVN closed up 5.12 percent on Tuesday, April 23, 2019, on 1.54 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BHVN trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week High Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Multiple of Ten Bullish Other 5.12%
Wide Bands Range Expansion 5.12%
Overbought Stochastic Strength 5.12%
Calm After Storm Range Contraction 6.38%
Upper Bollinger Band Walk Strength 6.38%

Older signals for BHVN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Neurodegenerative Diseases Riluzole
Is BHVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 64.54
52 Week Low 25.6
Average Volume 592,462
200-Day Moving Average 39.8575
50-Day Moving Average 49.7904
20-Day Moving Average 53.9405
10-Day Moving Average 57.212
Average True Range 2.7929
ADX 30.19
+DI 39.5404
-DI 11.653
Chandelier Exit (Long, 3 ATRs ) 56.16130000000001
Chandelier Exit (Short, 3 ATRs ) 55.8887
Upper Bollinger Band 64.3171
Lower Bollinger Band 43.5639
Percent B (%b) 0.98
BandWidth 38.474245
MACD Line 3.565
MACD Signal Line 2.5209
MACD Histogram 1.0441
Fundamentals Value
Market Cap 2.29 Billion
Num Shares 35.8 Million
EPS -7.54
Price-to-Earnings (P/E) Ratio -8.49
Price-to-Sales 0.00
Price-to-Book 5.62
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 69.18
Resistance 3 (R3) 68.78 66.66 68.31
Resistance 2 (R2) 66.66 65.34 66.86 68.02
Resistance 1 (R1) 65.33 64.53 66.00 65.73 67.74
Pivot Point 63.21 63.21 63.54 63.41 63.21
Support 1 (S1) 61.88 61.89 62.55 62.28 60.26
Support 2 (S2) 59.76 61.08 59.96 59.98
Support 3 (S3) 58.43 59.76 59.69
Support 4 (S4) 58.83